W. KantakamalakulJ. CoxU. KositanontS. SiritantikornK. LimbachD. BirxP. ThongcharoenP. PuthavathanaMahidol University2018-09-072018-09-072001-08-14Asian Pacific Journal of Allergy and Immunology. Vol.19, No.1 (2001), 17-220125877X2-s2.0-0034920984https://repository.li.mahidol.ac.th/handle/20.500.14594/26559The HIV-1 prime boost phase I/II vaccine trial using a recombinant canarypox vector, vCP1521, containing subtype E env (gp120), and subtype B env (gp41), gag and protease has started in Thailand. We have demonstrated that although 4 from 15 human immunodeficiency virus type 1 (HIV-1) seronegative individuals showed cytotoxic T lymphocyte (CTL) responses to vaccinia virus antigens, none of them showed specific CTL responses to subtype E Env after in vitro stimulation. This preliminary study suggests that specific CTL responses to subtype E envelope detected in HIV-1 seronegative individuals after vaccination should be considered as specific responses to the immunization.Mahidol UniversityImmunology and MicrobiologyMedicineArticleSCOPUS